• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Exclusives
    • Nutraceuticals
    • Markets
    • Health
    • Jobs
    • Events
    • Buyers' Guide
    • Showcases
    • More
  • Magazine
  • News
  • Exclusives
  • Nutraceuticals
  • Markets
  • Health
  • Jobs
  • Events
  • Buyers' Guide
  • Showcases
  • Current & Past Issues
    Features
    Columns
    Editorials
    Digital Edition
    Subscribe Now
    Advertise Now
    eNewsletter
    Editorial Guidelines
    Top Features
    Supporting Musculoskeletal Health: Tending to Muscles, Joints, and Bones

    2023 Contract Manufacturing Survey

    Dosage and Delivery Innovations Help Manufacturers Meet Common Challenges

    A Paradigm Shift for Antioxidants?

    Manufacturing Dietary Supplements in Economic Uncertainty
    Breaking News
    Certifications, Approvals and Patents
    Exclusives
    Industry & Market News
    People
    Products
    Regulatory
    Glossary
    Research
    Supplier News
    Supplier Insights
    Live From Shows
    Top News
    NPA: ‘Major Victory’ in Colorado After Amendment to Eating Disorder Bill

    GOOD Meat Receives FDA Go-Ahead for Cultured Meat

    IFF Achieves Industrial-Scale Production of Anaerobic Probiotic Strain

    Jones Healthcare Group Primed to Help Nutraceutical Brands Comply with New Packaging Rules

    Nordic Naturals Debuts Probiotic Line in More Than 375 Sprouts Farmer’s Markets
    Exclusives
    Blogs & Guest Articles
    Health E-Insights
    Area Code 420
    eBook
    Antioxidants
    Dairy-Based Ingredients
    Enzymes
    Fatty Acids
    Fiber & Carbohydrates
    Green Foods
    Herbs & Botanicals
    Marine Nutraceuticals
    Minerals
    Omega 3s
    Probiotics & Prebiotics
    Proteins, Peptides, Amino Acids
    Sweeteners
    Vitamins

    Harmonizing the EU's Upper Limits For Micronutrients

    GOOD Meat Receives FDA Go-Ahead for Cultured Meat

    IFF Achieves Industrial-Scale Production of Anaerobic Probiotic Strain

    Nordic Naturals Debuts Probiotic Line in More Than 375 Sprouts Farmer’s Markets

    DolCas Biotech's Curcugen Featured in Beauty-From-Within Supplement
    Consumer Trends
    Contract Manufacturing
    Cosmeceuticals / Nutricosmetics
    Delivery & Dosage Technologies
    Dietary Supplements
    Flavors & Colors
    Functional Foods & Beverages
    Healthcare Trends
    Medical Nutrition
    Mergers & Acquisitions
    Natural/Organic
    Nutrition Bars
    Packaging
    Pet Nutraceuticals
    Quality & Safety
    Regulations
    Research
    Testing
    World Markets

    NPA: ‘Major Victory’ in Colorado After Amendment to Eating Disorder Bill

    Harmonizing the EU's Upper Limits For Micronutrients

    GOOD Meat Receives FDA Go-Ahead for Cultured Meat

    IFF Achieves Industrial-Scale Production of Anaerobic Probiotic Strain

    Jones Healthcare Group Primed to Help Nutraceutical Brands Comply with New Packaging Rules
    Bone & Joint Health
    Cancer Risk
    Cardiovascular Health
    Cognitive Function
    Diabetes & Blood Sugar Management
    Digestive Health
    Energy
    Eye Health
    Healthy Aging
    Immune Function
    Infant & Children's Health
    Inflammation
    Men's Health
    Mood Health & Sleep
    Oral Health
    Sexual & Reproductive Health
    Skin Health
    Sports Nutrition
    Weight Management/Weight Loss
    Women's Health

    NPA: ‘Major Victory’ in Colorado After Amendment to Eating Disorder Bill

    Nordic Naturals Debuts Probiotic Line in More Than 375 Sprouts Farmer’s Markets

    DolCas Biotech's Curcugen Featured in Beauty-From-Within Supplement

    NOW Tests Bromelain Supplements Purchased on Amazon

    Podcast: Erin Stokes, ND, on Natural Health Strategies and the Role for Dietary Supplements
    Industry Events
    Live From Show Events
    Webinars
    All Companies
    Categories
    Trade Associations
    Company Capabilities
    International Buyers Guide Companies
    Chenguang Biotech Group Co., Ltd.

    American FlexPack

    PhytoGaia Inc

    Aiya America, Inc. (Aiya Matcha)

    Bioenergy Life Science, Inc. (BLS)
    Companies
    Product Releases
    News Releases
    Literature / Brochures
    White Papers
    Jobs
    VIdeos
    Services
    Add New Company
    International Buyers Guide Companies
    Chenguang Biotech Group Co., Ltd.

    American FlexPack

    PhytoGaia Inc

    Aiya America, Inc. (Aiya Matcha)

    Bioenergy Life Science, Inc. (BLS)
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Digital Edition
      • eNewsletter Archive
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
    • Breaking News
    • Buyers' Guide
      • All Companies
      • Categories
      • Trade Associations
      • Company Capabilities
    • Nutraceuticals
      • Antioxidants
      • Dairy-Based Ingredients
      • Enzymes
      • Fatty Acids
      • Fiber & Carbohydrates
      • Green Foods
      • Herbs & Botanicals
      • Marine Nutraceuticals
      • Minerals
      • Omega 3s
      • Probiotics & Prebiotics
      • Proteins, Peptides, Amino Acids
      • Sweeteners
      • Vitamins
    • Markets
      • Consumer Trends
      • Contract Manufacturing
      • Cosmeceuticals / Nutricosmetics
      • Delivery & Dosage Technologies
      • Dietary Supplements
      • Flavors & Colors
      • Functional Foods & Beverages
      • Healthcare Trends
      • Medical Nutrition
      • Mergers & Acquisitions
      • Natural/Organic
      • Nutrition Bars
      • Packaging
      • Pet Nutraceuticals
      • Quality & Safety
      • Regulations
      • Research
      • Testing
      • World Markets
    • Health
      • Bone & Joint Health
      • Cancer Risk
      • Cardiovascular Health
      • Cognitive Function
      • Diabetes & Blood Sugar Management
      • Digestive Health
      • Energy
      • Eye Health
      • Healthy Aging
      • Immune Function
      • Infant & Children's Health
      • Inflammation
      • Men's Health
      • Mood Health & Sleep
      • Oral Health
      • Sexual & Reproductive Health
      • Skin Health
      • Sports Nutrition
      • Weight Management/Weight Loss
      • Women's Health
    • Online Exclusives
    • Webinars
    • Slideshows
    • Blogs & Guest Articles
    • Health E-Insights
    • Videos
    • Podcasts
    • Infographics
    • eBook
    • Whitepapers
    • Research
      • TrendSense
      • Monograph Center
      • White Papers
      • Research News
    • Jobs
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Supplier Showcases
      • Companies
      • Product Releases
      • News Releases
      • Literature / Brochures
      • White Papers
      • Jobs
      • VIdeos
      • Services
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Columns

    Confusion Over Cannabis & The Fate of CBD

    Fair and reasonable or not, FDA could very well be a major buzzkill in the CBD supplement sector.

    Confusion Over Cannabis & The Fate of CBD
    By Erik Goldman, Holistic Primary Care07.02.18
    “If you’re going to push the envelope, don’t be dumb about it.” That sums up attorney Ivan Wasserman’s most basic advice for dietary supplement companies selling cannibidiol (CBD) or any other cannabis-derived products.

    One could argue that from a regulatory viewpoint, CBD is the envelope. Anyone paying attention to this industry knows there are hundreds of supplement companies willing to push it. 

    This year’s Natural Products Expo West made plain the extent to which CBD has entered into and invigorated the supplement market. The practitioner channel is no exception: several major practitioner-only players, including Thorne Research and Designs for Health, have already launched cannabis/hemp-based products, and rumor has it that several others are following suit.

    Further, cannabis-specific companies, like Encore Life, have launched new practitioner-targeted CBD lines. And some wildly popular consumer-focused CBD brands like Charlotte’s Web are now marketing at integrative and functional medicine conferences alongside the well-established practitioner-facing nutraceutical companies. All of this is distinct from, though related to, the medical marijuana industry, which is also growing rapidly in states in which it is legal.

    In short, cannabis has a lot of people seeing green these days; except, of course, for the regulators—and a little drug company called GW Pharmaceuticals—who are definitely seeing red. The Federal government has shown every intention of spoiling the CBD supplement party, and GW is very likely to emerge the big winner.

    Seeing Green, Ignoring Red
    “Nothing is moving faster than CBD and cannabis,” said Mr. Wasserman, a partner with Amin Talati Upadhye. He has worked with several companies playing in the rapidly shifting CBD/cannabis space.

    Speaking at Holistic Primary Care’s recent Practitioner Channel Forum, he noted the cannabis category’s growth potential is more than matched by its regulatory complexity and its potential for oversteps, marketing misfires, and quality assurance nightmares.

    Exuberance about booming sales can easily woo companies to forget two essential rules: 1) don’t turn scientific communication into commercial speech; 2) don’t be false, misleading, or fraudulent in your marketing communications.

    In today’s turbo-charged CBD/cannabis space, Mr. Wasserman sees companies doing both.  Yes, there is a burgeoning body of medical research showing that CBD and other compounds derived from cannabis affect multiple physiological processes, and that they can offer benefits for people struggling with a wide range of physical and psychological conditions.

    But as with any supplement ingredient, scientific data are not a license to make disease claims. “Commercial speech”—even if based on good science—is rampant in the cannabis/CBD market, more so on the consumer/retail side than in the practitioner channel, where marketers are more cautious.

    But on both sides of that increasingly porous divide, there’s a gold rush around CBD and cannabis. Some marketers are either forgetting that disease-focused claims are illegal, or in the spirit of marijuana’s outlaw status, they’re choosing to cross the line.

    And let’s face it: at the federal level, cannabis is still illegal. Todd Harrison, a partner with Venable LLP, who also spoke at the Forum, said the bottom line is that the Drug Enforcement Administration (DEA) still considers marijuana to be a Schedule 1 narcotic, despite any and all other state-level laws that rule otherwise. And by “marijuana,” the DEA means all parts of the Cannabis sativa plant—the seeds, the leaves, the stalks, the resin, everything.

    Strange Politics
    Despite all industry arguments to the contrary, “Hemp” and Cannabis are the same in the eyes of the law. The sole difference is the relative content of tetrahydrocannabinol (THC). To be recognized as “industrial hemp” the plant—and any extracts derived from it—must contain no more than 0.3% THC on a dry weight basis.

    The Hemp Industries Association (HIA) recently tried and failed to change the DEA’s classifications. Mr. Harrison explained that the HIA sought to have hemp extracts delisted as controlled substances on the grounds that the DEA’s classification was not consistent with the definition or intent of the definition of marijuana in the original Controlled Substances Act, and that it conflicted with industrial hemp provisions in the Agricultural Act (aka the Farm Bill). The 9th Circuit Court did not agree. “Basically, they punted,” Mr. Harrison said.

    In April, Senator Mitch McConnell (R-KY) introduced the Hemp Farming Act of 2018 into the Senate, with an identical bill brought to the House. The bill would exempt hemp (containing less than 0.3% THC) from the federal definition of “marijuana” under the Controlled Substances Act. It would give state governments and Native American tribal authorities primary regulatory authority over production of hemp, and the opportunity to submit proposals to the U.S. Secretary of Agriculture detailing how they would regulate hemp production and distribution.
    The bill induced euphoria among many in the hemp industry, leading some to canonize the arch-conservative Sen. McConnell as the new patron saint of herb.

    But as with just about everything else on today’s legislative scene, the Hemp Farming Act is a political football. Senator Chuck Grassley (R-IA) opted to break ranks with Sen. McConnell and introduced an amendment that would explicitly exclude “cannabinoids,”  “extracts,” and “derivatives” from the Farm Bill’s definition of industrial hemp; that basically means CBD. Sen. Grassley’s amendment was shot down in the Senate committee hearings, but the Iowa senator said he remains committed to pushing for these exclusions.

    Mr. Harrison, who works in D.C., believes Sen. McConnell’s hemp bill will ultimately pass. It has bipartisan support—Senate minority leader Chuck Schumer (D-NY) is on board—and won’t likely run into any opposition from the Oval Office. “I don’t think Trump cares one way or the other.”

    Drug or Dietary Supplement?
    So, yes, hemp will likely be de-scheduled. But that won’t change the game much for companies marketing CBD or any hemp-derived substances as dietary supplements. First, CBD is derived from the resin of the cannabis plant, not the seeds, so any company claiming to have “seed-derived CBD oil” is selling hemp seed oil with added CBD.

    And since, by DEA statutes, the resin counts as “marijuana,” CBD counts as “marijuana” despite the wishes of the cannabis industry and its many millions of customers. Further, low-THC hemp strains tend to produce very little CBD-containing resin, which means that most CBD will be coming from straight-up cannabis, not “hemp.”

    Second, while Sen. McConnell’s bill would redefine hemp as distinct from marijuana, it says nothing about the freedom to market hemp-derived products, despite what the marijuana lawyers will tell you. If it all sounds like a big game of semantics, it is. But the words and definitions are delineating the terms of engagement in the market, and the positions that regulators are going to take.

    Mr. Harrison said there’s currently no legitimate way to claim CBD is a dietary supplement. The FDA has made it very clear that it does not consider CBD to be a dietary supplement, based on the fact that GW Pharmaceuticals had filed Investigational New Drug applications for its CBD-based drug products years back in 2014. The company’s Sativex (Nabiximols)—an oral spray for use to treat pain and spasticity in people with multiple sclerosis—was approved as a drug in the U.K. in 2010.

    FDA approved the company’s Epidiolex product as a prescription form of CBD for childhood epilepsy at the end of June.

    Basically, the FDA has taken the position that since GW has developed CBD as a prescription drug, it cannot therefore be sold as a supplement unless a company can definitively prove that it was marketing CBD as a dietary supplement or conventional food before GW’s INDs were authorized. That, according to Mr. Harrison, is going to be a difficult feat.

    With GW’s Epidiolex approved as a prescription drug, one could expect tougher enforcement action against companies selling CBD as a supplement. FDA probably won’t take issue with companies selling hemp seed or hemp seed oil as foods, according to Mr. Harrison.

    It will be much harder to make the case that hemp stalks, leaves or flowers—which contain the CBD-rich resin—are or ever were a food source for humans.

    Fair and reasonable or not, FDA could very well be a major buzzkill in the CBD supplement sector. Mr. Harrison expects the agency will feel a strong “duty to enforce” once it grants drug approval for Epidiolex. “If the FDA doesn’t enforce, they will have made a mockery of the Food, Drug and Cosmetic Act.”

    In the meantime, sales of CBD are booming. Retailers speaking at a CBD Summit that preceded Expo West this year noted that CBD products are moving off the shelves as fast or even faster than more common—and less controversial—supplements like omega-3s or probiotics.

    The surge is driven in part by consumers’ fears that once Epidiolex is approved, CBD will no longer be freely available without prescription.

    Practitioner Perspectives
    How do medical professionals feel about cannabis and CBD? According to Holistic Primary Care’s 2018 clinician survey, the attitudes are generally positive, at least among holistic and functional medicine practitioners. Many are already on board with CBD, and others are interested and willing to learn.

    The survey, which fielded from March through May of this year, and obtained responses from 469 practitioners, included the following question: “In recent years, interest in cannabis and cannabis-derived substances like CBD has soared among researchers, clinicians, and the general public. Which statement best describes your views on Cannabis and CBD?”
    • 56% chose “CBD & cannabis-derived substances have therapeutic value and should be used more widely”;
    • 26% chose “CBD & cannabis have clinical value, but should only be available by prescription from a licensed practitioner”;
    • 17% chose “I am not yet convinced that CBD or cannabis have therapeutic value, but I am open to seeing further research”;
    • 2% chose “Neither cannabis nor CBD have therapeutic benefits; they are drugs of abuse and do not belong in any legitimate medical practice.
    The MD subset (33% of total cohort) were somewhat less likely than the general cohort to advocate for wide use of CBD and cannabis derivatives (47% vs 56%), and somewhat more inclined to support Rx-only status (34% vs 26%).

    But overall, acceptance of CBD and, to a lesser extent medical cannabis, as legitimate medicine is quite high among today’s clinicians. Only a small percentage sees these substances exclusively as noxious drugs of abuse. One quarter (24%) of respondents said they are already dispensing or recommending CBD but not cannabis itself. Only 1% are recommending or dispensing cannabis but not CBD.

    Nearly one-third (29%) are recommending or dispensing both CBD and cannabis, and 28% are considering the possibility of recommending or dispensing CBD or other cannabis products.
    Are practitioners who dispense or recommend CBD supplements crossing legal lines? They could be. While regulators are generally unwilling to interfere with practitioner-patient relationships, or challenging the “learned intermediary” status that medical professionals hold, they might feel emboldened to do so in the case of cannabis-related products, especially in the wake of a newly approved Rx-only product.

    Mr. Harrison believes physicians are taking some legal risk in “marketing an ingredient the DEA considers a controlled substance.” He added that companies selling these products to and through doctors are also taking calculated risks.

    Whether the laws are reasonable or not, whether they serve the best interests of practitioners or patients is certainly up for debate. What’s not debatable is the public’s interest in and desire for freely accessible non-Rx forms of CBD. But from a practical point of view, what really matters is the scope and intensity of FDA and DEA enforcement of existing statutes around CBD and cannabis.

    It remains to be seen whether federal agencies will continue to permit widespread sale of non-Rx CBD as dietary supplements, and frankly whether they have the budgets and personnel needed to do much more than issue a lot of stern warning letters. 


    Erik Goldman
    Holistic Primary Care

    Erik Goldman is co-founder and editor of Holistic Primary Care: News for Health & Healing, a quarterly medical publication reaching about 60,000 physicians and other healthcare professionals nationwide. He is also co-producer of the Practitioner Channel Forum, the nation’s leading conference focused on opportunities and challenges in the practitioner segment of the dietary supplement industry. 
    Related Searches
    • Regulatory
    • Omega-3s
    • survey
    • fda
    Related Knowledge Center
    • Herbs & Botanicals
    • Dietary Supplements
    • Medical Nutrition
    • Regulations
    Suggested For You
    House Reps Try Again to Regulate CBD and Other Hemp Derivatives as Dietary Ingredients House Reps Try Again to Regulate CBD and Other Hemp Derivatives as Dietary Ingredients
    Disappearing Act: The Battle Over Dietary Supplement Ingredients and the Drug Exclusion Provision Disappearing Act: The Battle Over Dietary Supplement Ingredients and the Drug Exclusion Provision
    Food Standards Agency Validates Novel Food Applications of Association for the Cannabinoid Industry Food Standards Agency Validates Novel Food Applications of Association for the Cannabinoid Industry
    CENTR Expands Beverage Portfolio with Enhanced Water for Cognitive Function and Mood Support CENTR Expands Beverage Portfolio with Enhanced Water for Cognitive Function and Mood Support
    Naomi Whittel Named O&N Health Board of Directors President Naomi Whittel Named O&N Health Board of Directors President
    Amazon Bans Dietary Supplements Containing NMN Amazon Bans Dietary Supplements Containing NMN
    Common Sense Solutions to Regulating Cannabis and CBD Common Sense Solutions to Regulating Cannabis and CBD
    NPA Announces Annual Capitol Hill Advocacy ‘Fly-In’ Day NPA Announces Annual Capitol Hill Advocacy ‘Fly-In’ Day
    CBD Expectations: What Happens at FDA and Congress After Agency Seeks New Regulatory Pathway? CBD Expectations: What Happens at FDA and Congress After Agency Seeks New Regulatory Pathway?
    Natural Products Association Blasts FDA for Punting CBD Issues to Congress Natural Products Association Blasts FDA for Punting CBD Issues to Congress
    FDA Denies CBD Petitions, Cites Safety Concerns, Looks to Congress for New Regulatory Pathway FDA Denies CBD Petitions, Cites Safety Concerns, Looks to Congress for New Regulatory Pathway
    2023 Expectations For Wellness, Supplements, CBD, and the Broader Economy 2023 Expectations For Wellness, Supplements, CBD, and the Broader Economy
    Open Book Extracts and Purissima Announce Study on Cannabinoids and Menstrual Pain Open Book Extracts and Purissima Announce Study on Cannabinoids and Menstrual Pain
    Regulatory Challenges Persist for Dietary Supplement Stakeholders Regulatory Challenges Persist for Dietary Supplement Stakeholders
    Top Trends in CBD: 2022 Market Year in Review Top Trends in CBD: 2022 Market Year in Review

    Related Breaking News

    • Breaking News | Herbs & Botanicals | Regulations | Regulatory News
      House Reps Try Again to Regulate CBD and Other Hemp Derivatives as Dietary Ingredients

      House Reps Try Again to Regulate CBD and Other Hemp Derivatives as Dietary Ingredients

      After FDA punted CBD back to Congress in January, two House members are floating a pair of bills on the hill.
      03.20.23

    • Antioxidants | Dietary Supplements | Herbs & Botanicals | Regulations | Regulatory News | Vitamins
      Disappearing Act: The Battle Over Dietary Supplement Ingredients and the Drug Exclusion Provision

      Disappearing Act: The Battle Over Dietary Supplement Ingredients and the Drug Exclusion Provision

      Increasingly, FDA has used this ‘race to market’ language of DSHEA to prevent or remove safe and legitimate dietary ingredients from commerce.
      By James J. Gormley, Gormley NPI Consulting 03.16.23

    • Breaking News | Herbs & Botanicals | Regulations | Regulatory News | World Markets
      Food Standards Agency Validates Novel Food Applications of Association for the Cannabinoid Industry

      Food Standards Agency Validates Novel Food Applications of Association for the Cannabinoid Industry

      Applications for authorization of CBD isolate and distillate in the UK will now move on to the risk assessment stage to be further assessed.
      03.14.23


    • Cognitive Function | Functional Foods & Beverages | Herbs & Botanicals | Mood Health & Sleep | Proteins, Peptides, Amino Acids
      CENTR Expands Beverage Portfolio with Enhanced Water for Cognitive Function and Mood Support

      CENTR Expands Beverage Portfolio with Enhanced Water for Cognitive Function and Mood Support

      The drinks feature several science-backed ingredients, including citicoline and GABA.
      By Mike Montemarano, Associate Editor 03.07.23

    • Breaking News | Natural/Organic | People News
      Naomi Whittel Named O&N Health Board of Directors President

      Naomi Whittel Named O&N Health Board of Directors President

      Sandra Baek Lee, CEO of NJ Labs, has also been appointed as a new board member.
      03.01.23

    Loading, Please Wait..
    Trending
    • Shiitake Mushroom Extract Appears Helpful In HPV Infections
    • The Functional Chocolate Company Launches Painfree Chocolate
    Breaking News
    • NPA: ‘Major Victory’ in Colorado After Amendment to Eating Disorder Bill
    • GOOD Meat Receives FDA Go-Ahead for Cultured Meat
    • IFF Achieves Industrial-Scale Production of Anaerobic Probiotic Strain
    • Jones Healthcare Group Primed to Help Nutraceutical Brands Comply with New Packaging Rules
    • Nordic Naturals Debuts Probiotic Line in More Than 375 Sprouts Farmer’s Markets
    View Breaking News >
    CURRENT ISSUE

    March 2023

    • Supporting Musculoskeletal Health: Tending to Muscles, Joints, and Bones
    • Dosage and Delivery Innovations Help Manufacturers Meet Common Challenges
    • 2023 Contract Manufacturing Survey
    • Manufacturing Dietary Supplements in Economic Uncertainty
    • Beyond Antioxidants: The Power of Berries
    • A Paradigm Shift for Antioxidants?
    • Ayana Bio on Path to Scale Bioactives Derived from Plant Cell Cultures
    • Nuritas: Leveraging Artificial Intelligence to Speak the Language of Life
    • Dietary Supplement Quality Assurance Programs Critical to Natural Products Industry Success
    • Innovation in Nutraceuticals: Dose Forms and Application Science Help Meet Consumer Demand
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    NPA: ‘Major Victory’ in Colorado After Amendment to Eating Disorder Bill
    GOOD Meat Receives FDA Go-Ahead for Cultured Meat
    IFF Achieves Industrial-Scale Production of Anaerobic Probiotic Strain
    Coatings World

    Latest Breaking News From Coatings World

    HOFFMANN MINERAL to Focus on Comprehensive Sustainability Strategy
    HMG and Prodrive Renew Technical Partnership
    Eastern Coatings Show Sets Schedule for Technical Papers
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    MPO's Most-Read Stories This Week—March 25
    Getinge iCast Receives FDA Premarket Approval
    Tessy Plastics Corp. Celebrates 50th Anniversary
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Willow, Suanfarma Complete Manufacturing Process for Cannabigerol
    Berkshire Sterile to Install nearly 1,500 solar panels at Massachusetts site
    Harm Reduction Therapeutics, Catalent Ink Naloxone Commercial Supply Pact
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Interpack 2023 Introduces New Special Areas and Activities
    eSalon Expands into Over 1,900 CVS Stores Nationwide
    The RealReal Discontinues Beauty Business
    Happi

    Latest Breaking News From Happi

    Clairol Announces First Global Haircare Campaign in Five Years
    Nair’s Prep & Smooth Hair Removal, Walmart’s Accelerator
    ‘Glossier You’ Returns to Glossier’s Fragrance Portfolio
    Ink World

    Latest Breaking News From Ink World

    Weekly Recap: Packaging Inks, Toyo Ink Top This Week’s Stories
    Eastern Coatings Show Announces Schedule for Technical Papers
    Pulse Roll Label Products Adds Sean Labas to Technical Sales Team
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Imageworx details new facility, Avery Dennison tackles recycling and more
    TLMI announces 2022 Eugene Singer Award winners
    Pulse Roll Label Products expands technical sales team
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Weekly Recap: Heartland Polymers Begins Production, Zeta Polimeri Becomes Radici EcoMaterials & More
    Heartland Polymers Begins Production in Alberta
    Zeta Polimeri Becomes Radici EcoMaterials
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    ODT's Most-Read Stories This Week—March 25
    AI is Effective at Documenting Orthopedic Encounters in Hand Surgery
    3D LifePrints Rebrands to Insight Surgery & Launches New Business in Houston
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Weekly Recap: Dave Rahami, Zebra, Dracula Technologies Top This Week’s Stories
    Midsummer, UCLA Collaborate on Perovskite-CIGS Tandem Solar Cells
    HID Reports on Reshaping the Security Industry

    Copyright © 2023 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login